'''Milacemide''' ([[International Nonproprietary Name|INN]])<ref>{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances. Supplement to ''WHO Chronicle'', 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23|url=http://www.who.int/medicines/publications/druginformation/innlists/RL23.pdf|publisher=World Health Organization|accessdate=8 January 2016|page=6}}</ref> is an [[MAO-B]] inhibitor and [[glycine]] [[prodrug]].<ref name=Dysken>{{cite journal|last=Dysken|first=MW|author2=Mendels, J |author3=LeWitt, P |author4=Reisberg, B |author5=Pomara, N |author6=Wood, J |author7=Skare, S |author8=Fakouhi, JD |author9=Herting, RL  |title=Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.|journal=Journal of the American Geriatrics Society|date=May 1992|volume=40|issue=5|pages=503â€“6|pmid=1634705}}</ref> It has been studied for its effects on human memory and as a potential treatment for the symptoms of [[Alzheimer's disease]].<ref>{{cite book|last=Harris|first=Carol Turkington ; foreword by Joseph R.|title=The encyclopedia of the brain and brain disorders|year=2002|publisher=Facts on File|location=New York, NY|isbn=0-8160-4774-X|url=https://www.scribd.com/doc/10098801/The-Encyclopedia-of-the-Brain-and-Brain-Disorders|edition=2nd}}</ref> Early clinical trials did not show positive results however,<ref name=Dysken/> and the drug is now abandoned.
